Systematic Financial Management LP lessened its stake in shares of Orthofix International N.V. (NASDAQ:OFIX) by 25.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,620 shares of the medical device company’s stock after selling 10,485 shares during the period. Systematic Financial Management LP owned about 0.17% of Orthofix International worth $1,447,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of OFIX. UBS Asset Management Americas Inc. acquired a new stake in Orthofix International during the 1st quarter worth about $229,000. Vanguard Group Inc. raised its holdings in Orthofix International by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 1,815,948 shares of the medical device company’s stock worth $69,278,000 after buying an additional 284,482 shares during the period. Dimensional Fund Advisors LP raised its holdings in Orthofix International by 2.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 779,771 shares of the medical device company’s stock worth $29,748,000 after buying an additional 20,473 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Orthofix International by 2.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 169,143 shares of the medical device company’s stock worth $6,453,000 after buying an additional 4,428 shares during the period. Finally, Bank of America Corp DE raised its holdings in Orthofix International by 834.2% during the 1st quarter. Bank of America Corp DE now owns 28,838 shares of the medical device company’s stock worth $1,100,000 after buying an additional 25,751 shares during the period. Hedge funds and other institutional investors own 94.59% of the company’s stock.

Several analysts have issued reports on OFIX shares. Zacks Investment Research downgraded Orthofix International from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. BTIG Research set a $56.00 target price on Orthofix International and gave the company a “buy” rating in a research note on Monday, October 30th. TheStreet cut Orthofix International from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. BidaskClub raised Orthofix International from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $55.00 target price (up previously from $50.00) on shares of Orthofix International in a research note on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $54.42.

In related news, CFO Rice Doug sold 7,353 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the sale, the chief financial officer now owns 44,743 shares of the company’s stock, valued at approximately $2,212,988.78. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Luke T. Faulstick sold 4,800 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $51.22, for a total value of $245,856.00. Following the completion of the sale, the director now directly owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,109 shares of company stock worth $953,440. Company insiders own 5.60% of the company’s stock.

Orthofix International N.V. (NASDAQ OFIX) opened at $54.15 on Thursday. Orthofix International N.V. has a 12 month low of $32.51 and a 12 month high of $54.73. The firm has a market capitalization of $981.01, a PE ratio of 35.17, a price-to-earnings-growth ratio of 2.67 and a beta of 0.15.

Orthofix International (NASDAQ:OFIX) last released its earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The company had revenue of $105.30 million for the quarter, compared to analysts’ expectations of $100.67 million. During the same quarter in the previous year, the business posted $0.36 EPS. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. sell-side analysts predict that Orthofix International N.V. will post 1.61 earnings per share for the current year.

WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/11/30/orthofix-international-n-v-ofix-holdings-cut-by-systematic-financial-management-lp.html.

Orthofix International Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).

Institutional Ownership by Quarter for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.